Trinity Capital, an international alternative asset manager, committed $35 million in growth capital to Monteris Medical, a MedTech company specializing in minimally invasive neurosurgical technology.
“We believe Monteris is advancing innovation across the life sciences sector with technology that is expanding treatment options in neurosurgery,” Rob Lake, senior managing director of life sciences at Trinity Capital, said. “We are proud to support a team that is not only pushing the boundaries of medical technology, but also delivering meaningful new treatment options for patients.”
The growth capital will help support Monteris Medical’s commercialization of the Neuroblate System and expansion of clinical research programs.
“Securing this new credit facility from Trinity Capital, alongside the support of our Series E equity investors, strengthens our ability to accelerate growth and continue delivering innovative, minimally invasive neurosurgical solutions for patients in need,” Martin J. Emerson, president and CEO of Monteris Medical, said. “Trinity’s partnership reflects strong confidence in our strategy, the NeuroBlate System, and the expanding clinical impact our technology is making across leading neuroscience centers. This financing ensures we can further invest in commercial expansion, product innovation and the teams who bring our mission to life every day.”
